AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00813267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell infusion
Study NCT00813267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow mononuclear cell infusion
Study NCT04329325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Please see detailed summary.
Study NCT04329325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Please see detailed summary.
Study NCT04329325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Please see detailed summary.
Study NCT04329325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Please see detailed summary.
Study NCT03764462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-101 45mg
Description: Raloxifene 45mg tablet
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCR
Description: 1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
Study NCT03764462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg
Description: Raloxifene 60mg tablet
Study NCT03896906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
Study NCT03896906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: simple mask
Description: Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
Study NCT02715804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Description: PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
Study NCT02715804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PEGPH20
Study NCT02715804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
Study NCT02715804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
Study NCT02715804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study NCT02715804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
Study NCT04115345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study NCT01048047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren/amlodipine
Description: aliskiren 300 mg /amlodipine 10 mg
Study NCT01048047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren/amlodipine
Description: aliskiren 300 mg /amlodipine 10 mg
Study NCT02607462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Study NCT02607462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03778580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxamine Dihydrochloride
Description: pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
Study NCT03778580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03369704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Study NCT03369704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
Study NCT00643097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEP-3 vaccine
Description: Given intradermally
Study NCT00643097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given intradermally
Study NCT00643097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard of care chemotherapy
Study NCT01283893 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic distal gastrectomy with D2 lymphadenectomy
Description: The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
Study NCT02325440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod: 0.5 mg p.o. (o.i.d)
Study NCT00002540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Examination
Description: Undergo DRE
Study NCT02325440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab: 300 mg i.v. (once at baseline);
Study NCT02758912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
Study NCT02949557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decortication + bone grafts
Study NCT05380908 — intervention group
Intervention type: OTHER
Intervention: None of any intervention
Description: The patients did not have any intervention.
Study NCT01816542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patch tests on healthy skin
Description: Patches will be placed on healthy skin.
Study NCT00002540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study NCT02932319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: The Foley cathter will be inserted at term + 4 days for 24 hours.
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asp
Description: 2,000 IU/m2 IV for ages \</= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A \& 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX
Description: 750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2 orally once daily on days 1-28 during Courses 1A \& 2A; Maintenance: Monthly, days 1-5
Study NCT02932319 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: expectative
Description: expectative until the next day befor starting the induction
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal AraC
Description: 25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B \& 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCV
Description: 50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
Study NCT00646581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00646581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin (Humulin)
Description: 40 IU Intranasal Insulin will be administered once
Study NCT03499613 — intervention group
Intervention type: OTHER
Intervention: Multidisciplinary rehabilitation program
Description: The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
Study NCT02517268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Study NCT02517268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AraC
Description: 2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C \& 2C
Study NCT02043587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 140 mg orally daily if BCR/ABL positive and/or Ph+
Study NCT04121689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Protein Concentrate
Description: The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
Study NCT00255034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Study NCT00255034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
Study NCT00255034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
Study NCT00255034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
Study NCT01398228 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: quality improvement initiatives
Description: A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
Study NCT01448707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
Study NCT01448707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
Study NCT01448707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
Study NCT01448707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
Study NCT03613818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO
Description: eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
Study NCT02066545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS001 Topical Gel
Study NCT02066545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CLS001 Topical Gel Vehicle
Study NCT03374761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families First Home Visiting Program
Description: 10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
Study NCT01703104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paludrine + Folic Acid
Description: This is the combination of routine drugs for treating sickle cell disease
Study NCT01703104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Paludrine + Folic Acid + Jobelyn
Description: Combination of routine drugs + Jobelyn
Study NCT02071641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT02871518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin combine with IMRT
Description: Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
Study NCT02871518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin combine with IMRT
Description: Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM oxytocin 10 IU
Description: IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 50 mcg
Description: IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 200 mcg
Description: IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 400 mcg
Description: IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IH oxytocin 600 mcg
Description: IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
Study NCT02542813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
Study NCT02058251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
Study NCT02058251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will self-administer a 40 IU dose of intranasal saline.
Study NCT00191386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Description: 0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
Study NCT03122249 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advanced Cancer Symptom Management
Description: For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
Study NCT02873208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
Study NCT00458367 — intervention group
Intervention type: DRUG
Intervention: Open label risperidone long acting injectable
Description: intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
Study NCT01680939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 0.2-0.5 mg/kg PO q4h
Study NCT01680939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10mg/kg PO q6hrs
Study NCT05625880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place
Study NCT01883219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKIs
Description: Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
Study NCT01394367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory and exercise therapy
Description: Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
Study NCT01427114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, vincristine, and prednisolone
Description: 6 cycles of R-CVP followed by 2 cycles of rituximab
Study NCT02915289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone Iodine
Description: Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
Study NCT02915289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
Study NCT04720690 — intervention group
Intervention type: DEVICE
Intervention: Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output
Description: Measurement of arterial stiffness and cardiac output
Study NCT04720690 — intervention group
Intervention type: DEVICE
Intervention: NICaS
Description: Measurement of cardiac output
Study NCT04720690 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography and ultrasound of arteries
Description: Measurement of cardiac output; measurement of intima-media thickness of arteries
Study NCT00814164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative Study
Study NCT01007097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
Study NCT01048255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-765
Description: 300mg Oral Tablet, 900mg TID
Study NCT00054418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: calcium 600 mg daily administered orally for one year
Study NCT00054418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: calcium 600 mg daily administered orally for one year
Study NCT00054418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: vitamin D 400 U daily administered orally for one year
Study NCT00054418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D 400 U daily administered orally for one year